DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first identified in the 1970s. It consists of 9 amino acids and has been studied for its potential role in regulating sleep, modulating stress responses, and influencing hormonal activity. While research suggests possible benefits for sleep quality, recovery, and stress reduction, DSIP remains experimental and is not FDA-approved for therapeutic use.

How It Is Used in Research Settings

• Explored in sleep research for its potential to promote deeper slow-wave sleep.
• Studied for reducing stress and supporting recovery through modulation of the hypothalamic-pituitary-adrenal (HPA) axis.
• Investigated for its influence on hormone regulation, including cortisol, luteinizing hormone (LH), and growth hormone (GH).
• Examined in pain and neuroprotection models for its potential calming and stabilizing effects on the nervous system.

Proposed Uses (Research Areas)

• Sleep research — improving sleep quality and slow-wave cycles.
• Stress modulation and recovery studies.
• Hormonal balance research, including GH and LH regulation.
• Neuroprotection and pain modulation models.

How It Is Dosed in Research Settings

• Injectable: Commonly studied at 100–500 mcg subcutaneously, often administered before bedtime.
• Cycle length: Research protocols vary from short-term (several days) to multi-week studies depending on sleep and stress endpoints.
• Alternative forms: Some studies have explored oral, intranasal, or IV administration, but injection remains the most studied route.
• Handling: Supplied as a lyophilized powder; reconstituted with bacteriostatic water and stored refrigerated per research SOPs.

Important Considerations

• Regulatory status: DSIP is not FDA-approved and remains experimental.
• Evidence base: Most studies are small-scale or preclinical; results have been mixed, with some showing improved sleep outcomes and others showing minimal effects.
• Safety: Generally well tolerated in research settings, with mild drowsiness reported. Long-term safety data is lacking.

Disclaimer

This material is provided for educational purposes only and summarizes published research on DSIP.
It is not medical advice. DSIP is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.

This peptide is for research use only.